181 related articles for article (PubMed ID: 10897004)
1. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Tumour Biol; 1994; 15(1):52-60. PubMed ID: 8146530
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
4. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
6. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
Nouts A; Lévy P; Voitot H; Bernades P
Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
[TBL] [Abstract][Full Text] [Related]
9. Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma.
van Heerde MJ; Buijs J; Hansen BE; de Waart M; van Eijck CH; Kazemier G; Pek CJ; Poley JW; Bruno MJ; Kuipers EJ; van Buuren HR
Dig Dis Sci; 2014 Jun; 59(6):1322-9. PubMed ID: 24385012
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
[TBL] [Abstract][Full Text] [Related]
11. TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; Einarsson R; van Dalen A
Int J Biol Markers; 2004; 19(2):115-9. PubMed ID: 15255543
[TBL] [Abstract][Full Text] [Related]
12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
13. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
Markocka-Maczka K
Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
[TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.
Kornek G; Schenk T; Raderer M; Djavarnmad M; Scheithauer W
Br J Cancer; 1995 Jan; 71(1):182-5. PubMed ID: 7529527
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
16. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
[TBL] [Abstract][Full Text] [Related]
17. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
18. Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?
Panucci A; Fabris C; Del Favero G; Basso D; Di Mario F; Marchioro L; Piccoli A; Lise M; Burlina A; Naccarato R
J Clin Pathol; 1986 Jan; 39(1):75-7. PubMed ID: 3950034
[TBL] [Abstract][Full Text] [Related]
19. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
